Autonomix Medical, Inc.
Autonomix Medical, Inc. is a development-stage medical device company building a catheter-based platform that combines neural sensing with radiofrequency ablation. Its lead program is designed to target pain associated with pancreatic cancer through a minimally invasive transvascular approach, with the broader goal of treating other nerve-related disorders as the platform matures. The company is still pre-commercial and is focused on proof-of-concept work, clinical development, and regulatory clearance. Autonomix’s business model is centered on disposable catheter sales to hospital catheter labs rather than large capital equipment placements.
Fiscal year 2026 · change from previous year
Development 2023–2026
Business
Share of revenueThe core platform combines diagnostic sensing with therapeutic RF ablation to identify and treat neural targets through a transvascular approach.
Single-use sensing and ablation catheters intended to be sold to hospitals and catheter labs as recurring procedure consumables.
RF energy source and software-enabled user interface used to power and control the catheter system.
Research, pre-clinical testing, and regulatory work supporting first indication approval and future label expansion.
Customers
Autonomix’s expected customers are hospitals and hospital catheter labs that perform interventional procedures. The company specifically expects interventional radiologists to be the primary users because the platform is designed to fit familiar catheter-based workflows and require limited training. The initial clinical and commercial focus is on patients with intractable pain associated with pancreatic cancer, but the buying decision is made by healthcare providers and hospital systems rather than patients directly. Over time, the company also targets broader interventional and specialty care settings if the platform is validated for additional indications such as hypertension, chronic pain, and other nerve-related disorders.
Buy the disposable catheter system and related components to perform interventional procedures with minimal capital equipment needs.
Primary clinical users who need a familiar catheter workflow and limited training to adopt the platform.
Would use the system for pancreatic cancer pain and other visceral pain indications if clinical validation and approvals are achieved.
Potential buyers for expanded indications such as hypertension, chronic pain, CRPS, and cardiology-related nerve targeting.
Strategy
Autonomix’s near-term strategy is to advance its lead catheter-based sensing and ablation platform through clinical trials and obtain regulatory clearance for its first indication. The company is concentrating first on pancreatic cancer pain because it offers a clear clinical need and a focused path to proof-of-concept. A second strategic priority is to preserve and expand intellectual property, including new U.S. patents covering controlled sympathectomy, micro-ablation, and neurological mapping. The company also needs to secure additional financing to fund development through commercialization, making capital formation a core execution priority rather than a side task.
Clinical validation is required to prove safety and efficacy and to support regulatory clearance and eventual commercialization.
The company states it needs substantial additional capital to fund operations through commercialization and avoid scaling back the business plan.
Patent protection is central to differentiating the platform against much larger electrophysiology competitors.
A broader indication set could increase the addressable market and improve the long-term commercial value of the platform.
Geography
Autonomix is headquartered in Texas and also has access to a research and development facility in Pennsylvania. The company’s current operating footprint is therefore U.S.-based, with clinical, regulatory, and commercialization efforts initially centered in the United States. Its trademark portfolio extends beyond the U.S. to Australia, China, the European Union, India, Japan, Mexico, and Singapore, which supports future international expansion but does not yet indicate meaningful revenue geography. Because the company is pre-commercial, geography currently matters more for where development work is performed and where regulatory approvals are pursued than for revenue concentration.
Risks
Autonomix faces the typical risks of a development-stage medical device company, including clinical failure, regulatory delay, and the possibility that the product never reaches commercial scale. The company explicitly highlights liquidity and going-concern pressure, since it expects to need substantial additional financing to continue operations and fund commercialization. It also faces intellectual property risk because larger competitors in electrophysiology have greater resources and could challenge patents or develop competing technologies. In addition, the company depends on third-party contractors, manufacturers, and clinical partners, so supply chain disruption, quality issues, or slow adoption by healthcare professionals could materially delay progress.
- Liquidity and going-concern riskImpact: CriticalLikelihood: High
The company states it will need additional financing to meet obligations and execute its business plan, and may need to scale back operations if funding is unavailable.
Exposure: Development-stage operations and commercialization plans
- Clinical and regulatory riskImpact: HighLikelihood: High
The lead product is still in development, and success depends on clinical trial outcomes and regulatory clearance.
Exposure: First indication and future label expansion
- Intellectual property riskImpact: HighLikelihood: Medium
The company must protect its sensing and ablation technology against infringement claims and competitive copying.
Exposure: Core platform and patent portfolio
- Competitive pressure from larger medical device companiesImpact: HighLikelihood: Medium
Established electrophysiology players have greater resources, commercial infrastructure, and R&D budgets.
Exposure: Electrophysiology and interventional neuromodulation markets
- Third-party manufacturing and contractor dependenceImpact: MediumLikelihood: Medium
Development work relies heavily on contract engineers, manufacturers, and research organizations, which can create execution and quality risk.
Exposure - Cybersecurity and data privacy riskImpact: MediumLikelihood: Low
The company relies on digital systems and may handle sensitive information, making it vulnerable to breaches and operational disruption.
Exposure: Internal systems and third-party service providers
Accounting
Judgemental itemsManagement must estimate costs for work completed but not yet invoiced, which affects R&D expense and accrued liabilities.
Impact: Can shift quarterly operating losses and balance sheet accruals
The company notes warrant expense and valuation of equity-related instruments as critical judgments, which can create non-cash gains or losses.
Impact: Can materially affect net income and volatility
As a small development-stage company, equity awards are an important compensation tool and can be a meaningful expense.
Impact: Raises operating expenses without immediate cash outflow
Most development costs appear to be expensed as incurred, which keeps earnings under pressure until commercialization.
Impact: Affects reported losses and comparability across periods
Similar listed companies
Publicly listed companies with a comparable business focus.
Stereotaxis, Inc.
STXS · Electromedical & Electrotherapeutic Apparatus
Stereotaxis designs and sells robotic magnetic navigation systems used in minimally invasive cardiac and endovascular procedures.
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
Advanced Biomed Inc.
ADVB · Services-Medical Laboratories
Agentix Corp.
AGTX · Biological Products, (No Diagnostic Substances)
Regenerex Pharma, Inc.
Pharmaceutical Preparations
Adagio Medical Holdings, Inc.
ADGM · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026